Sign up
Pharma Capital

N4 Pharma heads down on disappointing data from Viagra reformulation study

The full set of results haven’t been made available yet, but N4 told investors that “it is clear” from the initial data that its reformulation did not have the desired effect on ED sufferers
man with erectile dysfunction
N4 will go away and look at the formulation of the drug and if there is anything they can change

N4 Pharma PLC (LON:N4P) halved on Monday as initial data from an early-stage trial of one of its lead drugs disappointed.

The AIM-quoted company has been trying to tweak the current formulation of sildenafil – commonly known as Viagra – to get the erectile dysfunction treatment to work more quickly and for a longer period of time.

READ: N4 Pharma on the rise as it files patent application for premature ejaculation drug

N4 said it is yet to receive the full set of results, but “it is clear” from the data already received that its reformulation failed to meet the primary endpoints of the trial.

“This part of the process of drug reformulation is always going to be a challenge and whilst this preliminary data is clearly disappointing, we will need to see the full set of results expected around the end of August to understand the detailed implications for the formulation,” said chief executive Nigel Theobald.

“We will provide a further update once we have had a chance to review all the findings from the trial about the next steps we will take to reformulate the product.”

Theobald added that N4’s nuvec development program continues as planned with further results due later this year.

In early afternoon trading, N4 shares were off 53.7% to 10.65p.



Register here to be notified of future N4P Company articles
View full N4P profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.